Assessment of Serum Levels of Anti-Gliadin (IgA and IgG) and Interleukin-2 in Patients with Celiac Disease
DOI:
https://doi.org/10.46966/msjar.v5i2.189Keywords:
Celiac Disease, Prevalence, Gliadin, AntibodyAbstract
Background: Anti-gliadin antibodies (AGA) are essential for the screening of celiac disease (CD), but high AGA levels have also been seen in a number of immune-mediated cutaneous disorders, even in the absence of clinical signs of gastrointestinal illness. The study aimed to serum levels of anti-gliadin (IgA and IgG) in patients with celiac disease and factors associated with celiac disease.
Materials and methods: This study is case-control design was conducted in Al-Imam Ali Hospital, Imam AL-Sadiq Hospital, and Marjan Hospital. A convenience sampling of 146 samples. The study comprised from two groups include 73 patients with celiac disease (CD), 73 healthy controls. Every participant donated 5 mL of venous blood, which was placed in gel tubes (6ml). Tubed blood is centrifuged for 10 minutes at 3000 rpm. Serum for (Anti-gliadin) is stored in Eppendorf tubes at -20 ºC until thawing on ELISA day.
Results: The results reveal that patients had significantly higher mean Gliadin IgA antibody levels (5.121 ± 3.356) than controls (2.891 ± 1.438), at statistically significant P. value <0.001. Gliadin IgG antibodies were significantly higher in patients (7.312 ± 4.575) compared to controls (3.430 ± 2.111), p-value < 0.001. Furthermore, the results found that the results found that patients had significantly higher mean levels of IL-2 (28.940±11.743) than controls (21.452±3.171).
Conclusions: The present study found that anti-gliadin (IgA and IgG), and IL-2 levels were higher significantly in patients with celiac disease. Furthermore, the results reveal that the sensitivity of anti-gliadin (IgG) were higher compared to anti-gliadin (IgA).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jalal Sabr Eidan, Assist. Prof. Dr. Hawraa Ameer Mubark
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
